I-Mab Reports Full Year 2023 Financial Results and ...
I-Mab announced a strategic divestiture of its China assets, expected to close by March 2024, impacting its financials and pipeline. Key updates include uliledlimab's IND filing for NSCLC, givastomig's dose escalation study, and ragistomig's Phase 1 results. The company reported a net loss of RMB1,465.7 million for 2023, with cash reserves of RMB2.3 billion.
Reference News
I-Mab Reports Full Year 2023 Financial Results and ...
I-Mab announced a strategic divestiture of its China assets, expected to close by March 2024, impacting its financials and pipeline. Key updates include uliledlimab's IND filing for NSCLC, givastomig's dose escalation study, and ragistomig's Phase 1 results. The company reported a net loss of RMB1,465.7 million for 2023, with cash reserves of RMB2.3 billion.